Psychedelic Therapeutics Market in 2025 Detailed Study Analysis

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Psychedelic Therapeutics Market By Origin of Psychedelic Substance (Synthetic Substances and Natural Substances), Type of Psychedelic Substance (GHB, Ketamine, MDMA, Psilocybin, DMT, Ayahuasca and LSD), Target Therapeutic Area (Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders and Trauma)- Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, The Psychedelic Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.6 Billion by the year 2034 at a 15.6 % CAGR during the forecast period for 2025-2034.

Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1329

Psychedelic medicines encompass a range of substances-including both synthetic chemicals and plant-derived compounds-that are being explored as treatments for various mental health disorders such as resistant depression, addiction, panic disorder, anxiety, and post-traumatic stress disorder. These potent psychoactive agents alter perception, emotions, and cognitive functions, offering a promising alternative to traditional medications. Renewed interest in psychedelic therapies has emerged in modern medicine, driven in part by the need for natural alternatives and the increasing prevalence of mood and anxiety disorders, especially in the wake of the COVID-19 pandemic.

The global market for psychedelic medicines is poised for expansion due to a rising incidence of depression and chronic stress, which have led to higher rates of mental health conditions worldwide. Changes in lifestyles and improvements in quality of living are further fueling demand, as patients seek more effective, holistic treatment options. Additionally, increasing dependency on conventional psychiatric medications is driving interest in alternative therapies.

Robust research and development initiatives, along with the introduction of breakthrough drugs that have demonstrated efficacy in patients with severe psychological disorders, are expected to create significant growth opportunities.
In 2021, North America dominated the market. It was anticipated to retain its dominance during the projection period, owing to the increasing incidence of depression and mental disorders, improved mental health awareness, and a rise in research and development efforts. In addition, the increase in mental health-related activity in the healthcare industry to create innovative therapies bolstered regional growth.

Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1329

Major market players operating in the Psychedelic Therapeutics market include Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx, Inc., Douglas Pharmaceuticals Limited, The Emmes, Company, LLC, CaaMTech, COMPASS Pathways plc, Eleusis Benefit Corporation, AWAKN Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp., Mindset Pharma, BetterLife Pharma, Cybin, CB Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, PharmaTher, Field Trip Health, ATAI Life Sciences, GH Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences, Incannex Health, PsyBio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, MYND Life Science, Wesana Health, Psyched Wellness, HAVN Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc., Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, MAPS Public Benefit Corporation (PBC), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences, and Other Prominent Player

Key developments in the market:
• In March 2022, COMPASS Pathways plc entered into a long-term strategic agreement to establish The Centre for Mental Health Research and Innovation ("the Centre") to boost psychedelic research and create new mental health treatment modes in the United Kingdom. The Centre will speed research into developing psychedelic treatments, promote therapist training and certification, analyze real-world evidence, and prototype digital tools to facilitate personalized, predictive, and preventative care models.
• In Nov 2021, Seelos Therapeutics, Inc. and iX Biopharma Ltd. signed an exclusive licencing agreement. Wafermine, a sublingual racemic ketamine wafer, and further products integrating R- and S- enantiomers of ketamine using the WaferiX technology will be licenced to Seelos by iX Biopharma under the terms of the agreement.
• In May 2021, Mind Medicine (MindMed) Inc. announced the initiation of Project Angie to promote the research and development of psychedelics, including LSD, as pain treatments. MindMed is currently investigating two key therapeutic indications for pain treatment. MindMed is now putting up a pre-IND briefing package for its Phase 2a Proof of Concept trial, which it intends to submit to the FDA in the second half of 2021.
• In July 2020, Canabo Medical Inc. ("Canabo") was licenced as an administrator and prescriber of the antidepressant SPRAVATO® (esketamine) nasal spray by Janssen Pharmaceuticals, Inc. ("Janssen"). In addition, the U.S. Food and Drug Administration approved Janssen's SPRAVATO® for use as an oral antidepressant in adults with treatment-resistant depressive disorder (TRD), followed by the drug's release in Canada.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1329

Market Segments
Global Psychedelic Therapeutics Market by Origin of Psychedelic Substance Revenue (US$ Mn) Forecast 2025-2034
• Synthetic Substances
• Natural Substances
Global Psychedelic Therapeutics Market Based on Type of Psychedelic Substance Revenue (US$ Mn) Forecast 2025-2034
• GHB
• Ketamine
• MDMA
• Psilocybin
• DMT
• Ayahuasca
• LSD
• Other
Global Psychedelic Therapeutics Market Based on Target Therapeutic Area Revenue (US$ Mn) Forecast 2025-2034
• Depression and Anxiety Disorders
• Pain Disorders
• Sleep-Related Disorders
• Trauma
• Other
Global Psychedelic Therapeutics Market, by Region, 2025-2034 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Psychedelic Therapeutics Market, by Country, 2025-2034 (Value US$ Mn)
• U.S.
• Canada
Europe Psychedelic Therapeutics Market, by Country, 2025-2034 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Psychedelic Therapeutics Market, by Country, 2025-2034 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Psychedelic Therapeutics Market, by Country, 2025-2034 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Psychedelic Therapeutics Market, by Country, 2025-2034 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Get More Information:@
https://www.insightaceanalytic.com/report/global-psychedelic-therapeutics-market/1329

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG

Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

This release was published on openPR.